SeekingAlpha · Oct 28, 2026
Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy - Slideshow
2026-10-28. The following slide deck was published by Cumberland Pharmaceuticals Inc.
NYSE · CPIX
Cumberland Pharmaceuticals Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$4.44
Up+$0.13 (+3.02%)
Updated Nov 5, 2026, 4:15 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.02M
- P/E ratio
- -11.12
- Dividend yield
- 67.57%
- 52-week range
- $1.85 – $9.28
- Volume
- 450.24K
- Avg. volume
- 54.96K
Price performance · CPIX
CPIX price history
1M range · 0 trading sessions · Daily adjusted prices
CPIX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CPIX news
The latest Smart Investors Daily articles mentioning CPIX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CPIX research
Overview
Company profile and research snapshot.
Company profile
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 3, 2019 | B. Riley | Buy | — |
| Nov 18, 2019 | B. Riley FBR | Buy | — |
| Aug 17, 2018 | B. Riley FBR | Buy | — |
| Apr 17, 2018 | B. Riley FBR | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 27, 2026
Cumberland Pharmaceuticals: The FDA's Phase 3 Question Is Hard To Ignore
Cumberland Pharmaceuticals is now a clinical-stage company focused on ifetroban for DMD cardiomyopathy. Read why CPIX stock is a hold.
Yahoo · Oct 26, 2026
Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy
Cumberland Pharmaceuticals (NASDAQ:CPIX) said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular dystrophy, after the U.S. Food and Drug Administration granted the company’s request for rolling revie
Yahoo · Oct 26, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). The Company announced plans to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ifetroban as a potential treatm
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
